Kyowa Hakko expands Setria® Glutathione brand in Europe
March 21, 2017
Kyowa is pleased to announce the launch of its premium branded ingredient Setria® Glutathione in the European markets.
Setria® is a branded form of glutathione an antioxidant present in almost all cells of the body. Glutathione plays an important role in numerous bodily processes, including antioxidant protection, detoxification and immune system fortification. Glutathione may be depleted as a result of poor lifestyle choices, stress and natural ageing. Supplementation is needed if ones diet does not include abundant unprocessed fruit and vegetables.
Kyowa Hakko has been manufacturing glutathione since the 1960s using a patented fermentation process. This proprietary technology, several years in the making, further distinguishes Setria® glutathione from generic glutathione in the market. Setria is a high purity form of glutathione, vegetarian and allergen-free with no animal or human raw materials used. It is clinically tested and has been shown to increase the levels of glutathione in the blood when taken orally.
Setria® Glutathione is a unique tripeptide consisting of three important amino acids glutamic acid, cysteine and glycine. The name SETRIA comes from SET the balance + TRI, of tripeptides. In other words, SETRIA is a tripeptide that helps to set body’s glutathione back to balance.
Setria® Glutathione is already successfully sold in the USA and Asia as a key antioxidant ingredient and is now available to European dietary supplement market.
For more information about Setria® Glutathione, visit www.setriaglutathione.com
Citicoline is Novel Food Ingredient in Europe!
Düsseldorf, July 17th, 2014
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) delivered a scientific opinion on Citicoline as a novel food ingredient (NFI) and concluded that Citicoline is safe under the proposed uses and use levels (www.efsa.europa.eu/it/efsajournal/doc/3421.pdf ).
Commission Implementing Decision 2014/423/EU of 1 July 2014 authorising Kyowa Hakko Europe the placing on the market of Citicoline as a novel food ingredient under Regulation (EC) No 258/97 (http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:JOL_2014_196_R_0006&from=EN ).
Citicoline is intended to be used in food supplements aimed at adult population at a maximum level of 500 mg/day, and in foods for particular nutritional uses, specifically foods for special medical purposes, at a maximum level of 250 mg/serving, and with a maximum daily intake from these types of foods of 1 000 mg/day.
In United States, Kyowa Hakko USA, Inc. offers a proprietary form of Citicoline, Cognizin®, a pure, allergen-free GRAS ingredient that’s stable and effective. For more information, go to www.cognizin.com .